Association of rare MSH6 variants with familial breast cancer by Wasielewski, M. et al.
PRECLINICAL STUDY
Association of rare MSH6 variants with familial breast cancer
Marijke Wasielewski • Muhammad Riaz • Joyce Vermeulen • Ans van den Ouweland •
Ineke Labrijn-Marks • Renske Olmer • Linda van der Spaa • Jan G. M. Klijn •
Hanne Meijers-Heijboer • Dennis Dooijes • Mieke Schutte
Received: 8 September 2009 / Accepted: 2 November 2009 / Published online: 19 November 2009
 Springer Science+Business Media, LLC. 2009
Abstract Germline mutations in the mismatch repair
genes MLH1, MSH2, MSH6, and PMS2 predispose to
Lynch syndrome (also known as hereditary non-polyposis
colorectal cancer). Recently, we have shown that the
CHEK2 1100delC mutation also is associated with Lynch
syndrome/Lynch syndrome-associated families albeit in a
polygenic setting. Two of the ten CHEK2 1100delC posi-
tive Lynch syndrome families additionally carried a path-
ogenic MLH1 or MSH6 mutation, suggesting that
mutations in mismatch repair genes may be involved in
CHEK2 1100delC-associated cancer phenotypes. A phe-
notype of importance is hereditary breast and colorectal
cancer (HBCC), with the CHEK2 1100delC mutation
present in almost one-fifth of the families—again in a
polygenic setting. In order to evaluate the involvement of
MSH6 in polygenic CHEK2 cancer susceptibility, we, here,
have analyzed the entire MSH6 coding sequence for
genetic alterations in 68 HBCC breast cancer families.
Rare MSH6 variants, with population frequencies below
1%, were identified in 11.8% of HBCC breast cancer
families, whereas the same variants were identified in only
1.5% of population controls, suggesting that rare MSH6
variants are associated with HBCC breast cancer
(P B 0.00001). However, screening of the entire MSH6
coding sequence in 68 non-HBCC breast cancer families
showed a similar association (8.8 vs. *1.4% in controls,
P B 0.001), suggesting that rare MSH6 variants are not
confined to HBCC breast cancer. Together, our data sug-
gest that rare MSH6 variants may predispose to familial
breast cancer. However, none of the rare MSH6 variants are
obviously pathogenic, suggesting that a more subtle disease
mechanism may operate in breast carcinogenesis.
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Introduction
In 2002, we and others have identified the truncating
CHEK2 1100delC mutation as the first moderate-risk breast
cancer susceptibility allele, present in about 5% of Dutch
breast cancer families [1, 2]. In addition, we have shown
that the CHEK2 1100delC mutation was also present
among Lynch syndrome/Lynch syndrome-associated fam-
ilies and was particularly prevalent among breast cancer
families with a hereditary breast and colorectal cancer
(HBCC) phenotype (4 and 18%, respectively) [3, 4].
However, in each of these instances, CHEK2 1100delC
appeared to confer cancer risks in a polygenic setting.
The association of CHEK2 1100delC with colorectal
cancer phenotypes suggested known colorectal cancer
genes as likely candidates for polygenic CHEK2 cancer
susceptibility [4]. Germline mutations in the DNA mis-
match repair (MMR) genes MLH1, MSH2, MSH6, and
PMS2 have been identified as the major causes for Lynch
syndrome (previously also known as hereditary non-
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polyposis colorectal cancer, HNPCC; [5–7]). Interestingly,
in two of the ten CHEK2 1100delC-positive Lynch syn-
drome-associated families, we had also identified patho-
genic mutations in MHL1 or MSH6 [4]. Concomitance of
CHEK2 and MSH6 mutations had reportedly also been
identified in a Finnish breast cancer family and in the
colorectal cancer cell line HCT15 [8–11]. During repair of
DNA damage, activated CHEK2 is known to signal
BRCA1, which in turn acts as a scaffold protein for several
DNA damage response proteins, including MSH6 [12–14].
The close functional relation of CHEK2 and MSH6,
together with the observed concomitance of mutations in
the two genes suggested that MSH6 mutations may be
involved in CHEK2 polygenic cancer susceptibility. This
hypothesis was particular appealing for the HBCC pheno-
type as CHEK2 1100delC is prevalent among these fami-
lies, whereas MSH6 mutations are identified among Lynch
syndrome families that also include breast cancer [3, 15–
17]. Here, we therefore have screened the MSH6 gene for
genetic alterations in 68 HBCC and 68 non-HBCC breast
cancer families.
Patients and methods
Breast cancer families and population controls
One hundred thirty-six breast cancer families were selected
from 578 breast cancer families registered at the Rotterdam
Family Cancer Clinic at Erasmus MC. Breast cancer
families were classified as hereditary breast and colorectal
cancer (HBCC) families (n = 68) or non-HBCC families
(n = 68). All families included at least two-first or second-
degree relatives (DGRs) with breast cancer of whom at
least one was diagnosed before the age of 60 years. HBCC
families additionally included at least one patient with
breast and colorectal cancer or at least one patient with
colorectal cancer diagnosed before the age of 50 years who
is within second DGR of a breast cancer patient or at least
two colorectal cancer patients of whom at least one is
within second DGR of a breast cancer patient [3].
All breast cancer families were screened for germline
mutations in the BRCA1 and BRCA2 genes and the CHEK2
1100delC mutation, identifying 26 BRCA1 mutant families,
6 BRCA2 mutant families, and 18 families with the CHEK2
1100delC mutation. Two families were double mutant for
BRCA1 and the CHEK2 1100delC mutation. As part of our
matching procedure, mutant BRCA1, BRCA2, and CHEK2
1100delC families were equally divided over HBCC and
non-HBCC families. Pathogenic germline mutations in the
MLH1 and MSH2 genes were not identified in any of the 68
HBCC families. MLH1 and MSH2 mutation status had not
been determined for the 68 non-HBCC families.
All breast cancer families originated from the south-
western Netherlands and have consented to search for
cancer susceptibility genes. The 166 control individuals
were geographically matched to the familial breast cancer
cases and included spouses of heterozygous carriers of
cystic fibrosis gene mutations, ascertained through the
department of Clinical Genetics at Erasmus MC. The
medical ethical committee of Erasmus MC approved this
study.
MSH6 mutation analysis
The mismatch repair gene MSH6 (NM_000179.2) was
screened for mutations in blood-derived DNA of the
youngest diagnosed breast cancer case in the family (index
case). The complete coding sequence of the MSH6 gene,
including intron/exon boundaries up to 25 bases in the
intron, was amplified by standard PCR. Amplified frag-
ments were subsequently analyzed for genetic alterations
by denaturing gradient gel electrophoresis (DGGE) or by
direct sequencing as described [17–19]. Unique sequence
alterations were confirmed at least once by sequence
analysis of an independently generated PCR product. Pri-
mer sequences and reaction conditions are available upon
request.
Statistical analysis
The difference between the mutation frequency in breast
cancer patients versus controls was analyzed using Fisher’s
Exact Test. P values of 0.05 or smaller were considered
significant. All statistical analyses were performed with
STATA statistical package, release 10 (STATA Corp,
College Station, TX).
Results and discussion
Rare MSH6 variants associate with HBCC breast cancer
We analyzed the entire MSH6 coding sequence in 68 breast
cancer families with hereditary breast and colorectal cancer
(HBCC). Sequence analysis identified 25 different
sequence alterations among 68 HBCC families, including
10 intronic and 15 exonic variants (Table 1). In order to
evaluate the significance of the identified MSH6 variants
for HBCC, all variants were subsequently genotyped in 166
geographically matched controls. Rare variants, with pop-
ulation frequencies below 1%, represented 56% (14/25) of
the MSH6 variants and each of these were identified only
once or twice among the HBCC cohort. Four of the 14 rare
MSH6 variants identified among HBCC families were also
identified in the control cohort. Thus, although none of the
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Table 1 MSH6 mutation analysis among 68 HBCC and 68 non-HBCC breast cancer families
MSH6 gene sequencea Predicted protein effect Minor allele/Total tested alleles (%)
HBCC Non-HBCC All BRC Controls
Prevalent variants ([1%)
c.260 ? 22C [ G – 31/136 (22.8) 23/136 (16.9) 54/272 (19.9) 58/332 (17.5)
c.3438 ? 14A [ T – 58/136 (42.6) 58/136 (42.6) 116/272 (42.6) 126/322 (39.1)
c.3557-4dupT – 26/136 (19.1) 26/136 (19.1) 52/272 (19.1) 56/324 (17.3)
c.4002-10delT – 35/136 (25.7) 39/136 (28.7) 74/272 (27.2) 2/328 (25.6)
c.4002-10dupT – 14/136 (10.3) 16/136 (11.8) 30/272 (11.0) 41/312 (13.1)
c.116G [ A p.G39E 25/136 (18.4) 24/136 (17.6) 49/272 (18.0) 52/332 (15.7)
c.186C [ A p.= 31/136 (22.8) 23/136 (16.9) 54/272 (19.9) 58/332 (17.5)
c.276A [ G p.= 29/136 (21.3) 22/136 (16.2) 51/272 (18.9) 53/332 (16.0)
c.540T [ C p.= 42/136 (30.9) 39/136 (28.7) 81/272 (29.8) 95/332 (28.6)
c.642C [ T p.= 12/136 (8.8) 14/136 (10.3) 26/272 (9.6) 38/332 (11.4)
c.1286C [ G p.L396V 2/136 (1.5) 0/136 – 2/272 (0.7) 6/332 (1.8)
Rare variants (\ 1%)
Intronic (up to 25 bases)
c.457 ? 13A [ G – 1/136 (0.7) 0/136 – 1/272 (0.4) 1/332 (0.3)
c.3439-16C [ T – 2/136 (1.5) 0/136 – 2/272 (0.7) 0/306 –
c.3647-11T [ G – 0/136 – 1/136 (0.7) 1/272 (0.4) 0/254 –
c.4001 ? 12_4001 ? 15delACTA – 2/136 (1.5) 1/136 (0.7) 3/272 (1.1) 2/328 (0.6)
c.4002-10delTT – 1/136 (0.7) 0/136 – 1/272 (0.4) 0/312 –
c.4002-10delTTT – 0/136 – 1/136 (0.7) 1/272 (0.4) 1/312 (0.3)
c.4002-10delTTTT – 0/136 – 1/136 (0.7) 1/272 (0.4) 0/312 –
c.4002-10dupTTT – 1/136 (0.7) 1/136 (0.7) 2/272 (0.7) 0/312 –
Exonic synonymous
c.1053C [ T p.= 1/136 (0.7) 0/136 – 1/272 (0.4) 0/332 –
c.1164C [ T p.= 0/136 – 1/136 (0.7) 1/272 (0.4) 0/332 –
c.2272C [ T p.= 0/136 – 1/136 (0.7) 1/272 (0.4) 0/332 –
c.2775A [ C p.= 1/136 (0.7) 0/136 – 1/272 (0.4) 0/332 –
c.3246G [ T p.= 1/136 (0.7) 2/136 (1.5) 3/272 (1.1) 0/332 –
c.3306T [ A p.= 1/136 (0.7) 1/136 (0.7) 2/272 (0.7) 0/332 –
Exonic non-synonymous
c.73G [ T p.A25S 1/136 (0.7) 1/136 (0.7) 2/272 (0.7) 1/332 (0.3)
c.751A [ G p.I251 V 1/136 (0.7) 0/136 – 1/272 (0.4) 0/332 –
c.1508C [ G p.S503C 1/136 (0.7) 0/136 – 1/272 (0.4) 1/332 (0.3)
c.2045C [ T p.S682F 1/136 (0.7) 0/136 – 1/272 (0.4) 0/332 –
c.2633T [ C p.V878A 1/136 (0.7) 0/136 – 1/272 (0.4) 0/332 –
c.4072_4075dupGATT p.K1358fsX2b 0/136 – 1/136 (0.7) 1/272 (0.4) 0/332 –
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rare MSH6 variants associated significantly with HBCC fam-
ilies, the combined frequency of the rare variants was signifi-
cantly higher among HBCC families compared to controls
(16/136 (11.8%) vs. 5/306–332 (*1.5%), P\0.00001;
Table 1). These results suggested that rare MSH6 variants
may predispose for HBCC breast cancer.
Rare MSH6 variants associate with familial
breast cancer
In order to evaluate if rare MSH6 variants associate with
HBCC breast cancer or rather with familial breast cancer in
general, we also screened the entire MSH6 coding sequence
in 68 matched non-HBCC families (Table 1). Non-HBCC
families were matched to the HBCC families with respect
to their cancer pattern, i.e., the number of cancer patients
per family, the number of cancer patients overall and the
number of patients with single, double, triple, or more
cancers (Table 2). In order to avoid selection for HBCC,
the non-HBCC families have been counter selected for the
presence of colorectal cancer. Six additional rare MSH6
variants were identified among the non-HBCC families of
which only one was also identified among the controls
(Table 1). The combined frequency of rare MSH6 variants
was also significantly higher among non-HBCC families
compared to controls (12/136 (8.8%) vs. 4/254–332
(*1.4%), P \ 0.001; Table 1). Hence, the prevalence of
rare MSH6 variants among non-HBCC families is equally
high as among HBCC families, indicating that rare MSH6
variants are not only associated with HBCC breast cancer
but also more likely with breast cancer in general. Com-
bining the data on HBCC and non-HBCC families revealed
a prevalence of rare MSH6 variants of 10.3% among all
breast cancer families, whereas the same variants were
identified in approximately 2.1% of controls (P \ 0.0001;
Table 1), strongly suggesting that rare MSH6 variants may
predispose for familial breast cancer.
Do rare MSH6 variants predispose for familial
breast cancer?
Two aspects may question whether rare MSH6 variants
indeed predispose for familial breast cancer. First, we have
not screened the entire MSH6 coding sequence in the
control cohort. Our strategy had been to genotype in the
controls only those MSH6 variants that had been identified
among the familial breast cancer cohorts. Apart from the
genotyped variant sequence, our primer design allowed
analysis of the sequence surrounding the genotyped variant
often including entire exon sequences and intron sequences
up to 25 base pairs. In this way, we were able to analyze
75% of the MSH6 coding sequence in all controls. In
addition to the five rare MSH6 variants that already had
been identified in the breast cancer families, two variants
(c.59C [ T, p.A20 V and c.4002-10delCT) were once
identified exclusively among the controls. Based on this
low prevalence of rare MSH6 variants that are exclusively
present among the controls (2/254 (0.8%); Table 1), it may
be anticipated that screening of the remaining quarter of
the MSH6 coding sequence in the controls is unlikely to
identify many more rare MSH6 variants.
Another aspect is that the underlying disease mechanism
of how rare MSH6 variants may predispose to breast cancer.
We found that the prevalence of rare MSH6 variants was
Table 1 continued
Summary rare variants
Minor allele/Total tested alleles (%)
All Intronic Exonic all Exonic synonymous Exonic non-synonymous
HBCC families 16/136 (11.8) 7/136 (5.1) 9/136 (6.6) 4/136 (2.9) 5/136 (3.7)
Controls 5/306–332 (*1.5) 3/306–332 (*0.9) 2/332 (0.6) 0/332 (*0.0) 2/332–332 (0.6)
P value \0.00001
Non-HBCC families 12/136 (8.8) 5/136 (3.7) 7/136 (5.1) 5/136 (3.7) 2/136 (1.5)
Controls 4/254–332 (*1.4) 3/254–328 (*1.1) 1/332 (0.3) 0/332 (*0.0) 1/332 (0.3)
P value \0.001
All BRC families 28/272 (10.3) 12/272 (4.4) 16/272 (5.9) 9/272 (3.3) 7/272 (2.6)
Controls 6/254–332 (*2.1) 4/254–332 (*1.4) 2/332 (0.6) 0/332 (*0.0) 2/332 (0.6)
P value \0.0001
a Numbering of nucleotide changes according MSH6 GenBank sequence NM_000179.2
b Frame shift mutation is indicated by the first changed codon and the number of newly encoded codons, including premature termination codon X
This particular variant locates 30 in the gene sequence predicting a protein shortened with only two amino acids. BRC breast cancer, HBCC
hereditary breast and colorectal cancer
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consistently higher among the breast cancer families than
the controls, whether they were intronic or exonic and
whether they were synonymous or non-synonymous. How-
ever, none of the identified rare MSH6 variants are known
pathogenic mutations. Evaluation of each of the rare MSH6
variants with the splice prediction programs Berkeley Dro-
sophila Genome Project (www.fruitfly.org/seq_tools/splice.
html) and NetGene2 (www.cbs.dtu.dk./services/NetGene2/)
did not predict structural effects. It thus remains unclear how
these rare MSH6 variants exert their putative oncogenic
effect, particularly for the intronic variants and the non-
synonymous exonic variants. However, are obvious patho-
genic effects to be expected in a polygenic setting? Impor-
tantly, the statistical evidence from our analysis that rare
MSH6 variants associate with familial breast cancer is
compelling (P \ 0.001), strongly suggesting cancer predis-
position by rare MSH6 variants. Obviously, our analysis
requires replication in independent familial breast cancer
cohorts, and it also seems warranted to screen familial
colorectal cancer cohorts, with particular focus to rare
variants that are not obviously pathogenic. In this respect,
our current findings are consistent with a report by
Nevanlinna et al. in which 15 different MSH6 variants were
identified among 38 breast cancer families with colorectal
cancer and/or endometrial cancer [20]. Three of the
MSH6 variants classified as rare variants, including two
synonymous exonic variants and one intronic variant. The
prevalence of rare MSH6 variants in their familial breast
cancer cohort is similar to the prevalence we report here
(3/38 = 7.9 vs. 10.3% in our cohort) and supports our
conclusion that rare MSH6 variants are associated with
familial breast cancer. Their and our observations both seem
to point toward a currently unknown disease mechanism in
breast carcinogenesis such as modulation of transcript
expression levels or mediation of non-coding RNAs located
in the genomic regions associated with these variants.
Therefore, one may wonder whether this mechanism is
similar to the as-yet unresolved disease mechanism under-
lying the more prevalent low-risk breast cancer alleles that
recently have received much attention [21–26].
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